Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265361 | 0.94 | PTGS2 (0.45) | PTGS2SMN1; SMN2THRATHRBKMT2A | |
| SCHEMBL5270432 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5265561 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5267871 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5265513 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5272557 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5272022 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5266338 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5268487 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 | |
| SCHEMBL5266807 | 0.92 | THRA (0.44) | PTGS2THRATHRBNR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170311601-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | MERIAL INC. (US) | 2017-11-02 | — | — | US | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170311601-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | CYP3A7, CYP3A4, CYP3A5 | PTGS2 2462/4885SMN1; SMN2 2856/4885CYP1A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.